Crohn Disease
5 competing products in clinical development for Crohn Disease.
Pipeline by Phase
Pre-clinical2
Phase 22
Approved1
All Products (5)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| LY4395089 + Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC) | Eli Lilly | Phase 2 | Recruiting | 42 |
| Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate) | Celltrion | Approved | UNKNOWN | 39 |
| Ustekinumab 45 mg + Ustekinumab 90 mg | Celltrion | Pre-clinical | Recruiting | 33 |
| Ustekinumab | Sun Pharmaceutical | Pre-clinical | Recruiting | 33 |
| VTX958 + VTX958 + VTX958 Placebo | Ventyx Biosciences | Phase 2 | Terminated | 21 |